NASDAQ:KOD Kodiak Sciences (KOD) Stock Price, News & Analysis → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free KOD Stock Alerts $3.30 -0.44 (-11.76%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$3.25▼$3.7750-Day Range$3.19▼$7.4552-Week Range$1.37▼$9.80Volume442,495 shsAverage Volume349,539 shsMarket Capitalization$173.35 millionP/E RatioN/ADividend YieldN/APrice Target$5.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Kodiak Sciences alerts: Email Address Kodiak Sciences MarketRank™ Stock AnalysisAnalyst RatingReduce1.71 Rating ScoreUpside/Downside66.7% Upside$5.50 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.87Upright™ Environmental ScoreNews Sentiment0.52Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.07) to ($2.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.12 out of 5 starsMedical Sector344th out of 914 stocksBiological Products, Except Diagnostic Industry50th out of 153 stocks 2.9 Analyst's Opinion Consensus RatingKodiak Sciences has received a consensus rating of Reduce. The company's average rating score is 1.71, and is based on 1 buy rating, 3 hold ratings, and 3 sell ratings.Amount of Analyst CoverageKodiak Sciences has only been the subject of 2 research reports in the past 90 days.Read more about Kodiak Sciences' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for KOD. Previous Next 0.0 Dividend Strength Dividend YieldKodiak Sciences does not currently pay a dividend.Dividend GrowthKodiak Sciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKodiak Sciences has received a 73.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Kodiak Sciences is -0.87. Previous Next 2.0 News and Social Media Coverage News SentimentKodiak Sciences has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Kodiak Sciences this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for KOD on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kodiak Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders45.30% of the stock of Kodiak Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.06% of the stock of Kodiak Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Kodiak Sciences' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kodiak Sciences are expected to grow in the coming year, from ($4.07) to ($2.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kodiak Sciences is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kodiak Sciences is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioKodiak Sciences has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Kodiak Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About Kodiak Sciences Stock (NASDAQ:KOD)Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.Read More KOD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KOD Stock News HeadlinesMay 17 at 7:47 AM | finanznachrichten.deKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial ResultsMay 16 at 8:42 AM | investing.comKodiak Sciences (KOD) Earnings Dates & ReportsMay 16 at 2:01 AM | finanznachrichten.deKodiak Sciences Inc.: Kodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic RetinopathyMay 16 at 12:06 AM | investorplace.comKOD Stock Earnings: Kodiak Sciences Beats EPS for Q1 2024May 15, 2024 | prnewswire.comKodiak Sciences Announces Recent Business Highlights and First Quarter 2024 Financial ResultsMay 13, 2024 | prnewswire.comKodiak Sciences Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic RetinopathyMay 2, 2024 | prnewswire.comKodiak Sciences Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) PlatformApril 30, 2024 | msn.comFlorida officials monitor over 30% increase in wildlife callsApril 29, 2024 | msn.comTractor-trailers with no one aboard? The future is near for self-driving trucks on US roads.April 27, 2024 | investing.comKodiak Sciences Inc (KOD)April 26, 2024 | msn.comReport portrays mixed picture of Alaska’s huge seafood industryApril 26, 2024 | msn.comHow the Great Alaska Earthquake Shook Up ScienceApril 17, 2024 | msn.comKodiak Sciences (KOD) Price Target Increased by 11.84% to 4.34April 11, 2024 | finance.yahoo.comWill Kodiak Sciences (NASDAQ:KOD) Spend Its Cash Wisely?April 3, 2024 | yahoo.comAlaska schools could buckle down on civicsMarch 30, 2024 | msn.comAlaska Legislature boosts allowable payments from fund that covers fishers’ crew medical costsMarch 30, 2024 | seekingalpha.comKodiak Sciences Inc. (KOD) Q4 2023 Earnings Call TranscriptMarch 30, 2024 | markets.businessinsider.comBarclays Sticks to Their Sell Rating for Kodiak Sciences (KOD)March 29, 2024 | finance.yahoo.comQ4 2023 Kodiak Sciences Inc Earnings CallMarch 29, 2024 | theguardian.comSurge of new US-led oil and gas activity threatens to wreck Paris climate goalsMarch 28, 2024 | yahoo.comAlutiiq museum in Kodiak celebrates the past to connect with the futureMarch 28, 2024 | finanznachrichten.deKodiak Sciences Inc.: Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial ResultsMarch 28, 2024 | marketwatch.comKodiak Sciences Shares Fall 24% on 4Q EPS MissMarch 28, 2024 | benzinga.comWhy Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionMarch 28, 2024 | finance.yahoo.comKodiak Sciences Inc (KOD) Posts Q4 and Full Year 2023 Financial ResultsSee More Headlines Receive KOD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kodiak Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/19/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:KOD CUSIPN/A CIK1468748 Webkodiak.com Phone(650) 281-0850FaxN/AEmployees116Year FoundedN/APrice Target and Rating Average Stock Price Target$5.50 High Stock Price Target$12.00 Low Stock Price Target$2.00 Potential Upside/Downside+66.7%Consensus RatingReduce Rating Score (0-4)1.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-260,490,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-81.11% Return on Assets-45.38% Debt Debt-to-Equity RatioN/A Current Ratio10.12 Quick Ratio6.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.59 per share Price / Book0.72Miscellaneous Outstanding Shares52,530,000Free Float28,730,000Market Cap$173.35 million OptionableOptionable Beta2.25 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Victor Perlroth M.D. (Age 51)Co-Founder, Chairman, CEO & President Comp: $1.08MMr. John A. Borgeson CPA (Age 62)M.B.A., Senior VP, CFO & Secretary Comp: $667.52kDr. Michael S. Louie Ph.D.Senior VP of Digital Transformation & Chief Information OfficerDr. Hong Liang (Age 52)Senior Vice President of Discovery Medicine Comp: $300.71kDr. Stephen Raillard Ph.D.Senior Vice President of Chemical Development & ManufacturingMs. Almas Qudrat M.Sc.Senior Vice President of Quality OperationsDr. J. Pablo Velazquez-Martin M.D.Senior VP of Clinical Research & DevelopmentTracy ChienVP & Corporate ControllerMore ExecutivesKey CompetitorsFennec PharmaceuticalsNASDAQ:FENCCentury TherapeuticsNASDAQ:IPSCINmune BioNASDAQ:INMBElevation OncologyNASDAQ:ELEVOptheaNASDAQ:OPTView All CompetitorsInsiders & InstitutionsIkarian Capital LLCBought 63,705 shares on 5/17/2024Ownership: 0.907%Jacobs Levy Equity Management Inc.Sold 198,025 shares on 5/16/2024Ownership: 1.001%Nan Fung Group Holdings LtdBought 12,300 shares on 5/14/2024Ownership: 0.061%Acadian Asset Management LLCSold 185,412 shares on 5/10/2024Ownership: 3.280%Vanguard Group Inc.Bought 10,978 shares on 5/10/2024Ownership: 3.150%View All Insider TransactionsView All Institutional Transactions KOD Stock Analysis - Frequently Asked Questions Should I buy or sell Kodiak Sciences stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kodiak Sciences in the last year. There are currently 3 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "reduce" KOD shares. View KOD analyst ratings or view top-rated stocks. What is Kodiak Sciences' stock price target for 2024? 7 brokers have issued 12-month price objectives for Kodiak Sciences' shares. Their KOD share price targets range from $2.00 to $12.00. On average, they predict the company's stock price to reach $5.50 in the next year. This suggests a possible upside of 66.7% from the stock's current price. View analysts price targets for KOD or view top-rated stocks among Wall Street analysts. How have KOD shares performed in 2024? Kodiak Sciences' stock was trading at $3.04 at the beginning of the year. Since then, KOD stock has increased by 8.6% and is now trading at $3.30. View the best growth stocks for 2024 here. When is Kodiak Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our KOD earnings forecast. How were Kodiak Sciences' earnings last quarter? Kodiak Sciences Inc. (NASDAQ:KOD) announced its earnings results on Thursday, March, 28th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.86) by $0.27. What other stocks do shareholders of Kodiak Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kodiak Sciences investors own include Quest Diagnostics (DGX), Cronos Group (CRON), Deere & Company (DE), GrowGeneration (GRWG), Immunomedics (IMMU), Teck Resources (TECK), Abbott Laboratories (ABT), Ability (ABIL), AbbVie (ABBV) and When did Kodiak Sciences IPO? Kodiak Sciences (KOD) raised $126 million in an initial public offering (IPO) on Thursday, October 4th 2018. The company issued 9,000,000 shares at $13.00-$15.00 per share. Morgan Stanley and BofA Merrill Lynch served as the underwriters for the IPO and Barclays and Chardan were co-managers. Who are Kodiak Sciences' major shareholders? Kodiak Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (3.28%), Vanguard Group Inc. (3.15%), Jacobs Levy Equity Management Inc. (1.00%), Ikarian Capital LLC (0.91%), Los Angeles Capital Management LLC (0.25%) and Sei Investments Co. (0.22%). Insiders that own company stock include Bros Advisors Lp Baker, Jason Ehrlich, John A Borgeson and Victor Perlroth. View institutional ownership trends. How do I buy shares of Kodiak Sciences? Shares of KOD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KOD) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressShocking $16T Elon Musk Crypto LeakCrypto 101 Media[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders41 banks launch ‘crypto dollar’Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kodiak Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.